Prospective study to assess the optimal blood concentration of tacrolimus in Japanese patients with rheumatoid arthritis

Hitoshi Kawazoe, Hiroaki Dobashi, Tomohiro Kameda, Kentaro Susaki, Katuharu Kittaka, Michiaki Tokuda, Noriyasu Fukuoka, Toshihiko Ishida, Yoshiharu Takiguchi, Hitoshi Houchi

Research output: Contribution to journalArticle

Abstract

We performed a prospective study to assess the optimal blood concentration of tacrolimus in Japanese patients with rheumatoid arthritis (RA). The dose of tacrolimus (1-3mg/day) was administered orally once daily after the evening meal, and the blood concentration of tacrolimus 12 hr after administration was quantified. A total of 23 patients were enrolled. Clinical efficacy was assessed using the Disease Activity Score in 28 joints and European League Against Rheumatism (EULAR) response criteria at each outpatient visit during months 1-6. The ratio of patients who showed a moderate or good response was 47.8% (11/23). The mean blood concentrations of tacrolimus in EULAR responders and EULAR non-responders were 5.5±3.6 (mean±S.D.) and 3.1±1.9 ng/ml, respectively (p = 0.069). Interestingly, although tacrolimus had lower mean blood concentrations (< 5ng/ml) compared with transplant fields (10-20 ng/ml), six (35.3%) of 17 patients showed sufficient response to tacrolimus. In addition, in five patients, tacrolimus was co-administered with methotrexate (MTX). On the other hand, the mean blood concentrations of tacrolimus in patients who did or did not develop adverse events were 4.8±4.4 (n = 8) and 4.0±2.1 (n = 15) ng/ml, respectively (p = 0.624). We failed to clear the optimal blood concentration of tacrolimus in RA patients, but one of the most remarkable findings was the observation that patients in whom tacrolimus was combined with MTX reached a positive response at much lower tacrolimus concentrations compared to patients not co-treated with MTX.

Original languageEnglish
Pages (from-to)435-440
Number of pages6
JournalJournal of Health Science
Volume55
Issue number3
DOIs
Publication statusPublished - 2009 Jun 1
Externally publishedYes

Fingerprint

Tacrolimus
Rheumatoid Arthritis
Blood
Prospective Studies
Methotrexate
Rheumatic Diseases
Transplants
Meals
Outpatients
Joints

Keywords

  • Blood concentration
  • Rheumatoid arthritis
  • Tacrolimus
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Prospective study to assess the optimal blood concentration of tacrolimus in Japanese patients with rheumatoid arthritis. / Kawazoe, Hitoshi; Dobashi, Hiroaki; Kameda, Tomohiro; Susaki, Kentaro; Kittaka, Katuharu; Tokuda, Michiaki; Fukuoka, Noriyasu; Ishida, Toshihiko; Takiguchi, Yoshiharu; Houchi, Hitoshi.

In: Journal of Health Science, Vol. 55, No. 3, 01.06.2009, p. 435-440.

Research output: Contribution to journalArticle

Kawazoe, H, Dobashi, H, Kameda, T, Susaki, K, Kittaka, K, Tokuda, M, Fukuoka, N, Ishida, T, Takiguchi, Y & Houchi, H 2009, 'Prospective study to assess the optimal blood concentration of tacrolimus in Japanese patients with rheumatoid arthritis', Journal of Health Science, vol. 55, no. 3, pp. 435-440. https://doi.org/10.1248/jhs.55.435
Kawazoe, Hitoshi ; Dobashi, Hiroaki ; Kameda, Tomohiro ; Susaki, Kentaro ; Kittaka, Katuharu ; Tokuda, Michiaki ; Fukuoka, Noriyasu ; Ishida, Toshihiko ; Takiguchi, Yoshiharu ; Houchi, Hitoshi. / Prospective study to assess the optimal blood concentration of tacrolimus in Japanese patients with rheumatoid arthritis. In: Journal of Health Science. 2009 ; Vol. 55, No. 3. pp. 435-440.
@article{d4ac0152c9d144ef97ec12f26f03c844,
title = "Prospective study to assess the optimal blood concentration of tacrolimus in Japanese patients with rheumatoid arthritis",
abstract = "We performed a prospective study to assess the optimal blood concentration of tacrolimus in Japanese patients with rheumatoid arthritis (RA). The dose of tacrolimus (1-3mg/day) was administered orally once daily after the evening meal, and the blood concentration of tacrolimus 12 hr after administration was quantified. A total of 23 patients were enrolled. Clinical efficacy was assessed using the Disease Activity Score in 28 joints and European League Against Rheumatism (EULAR) response criteria at each outpatient visit during months 1-6. The ratio of patients who showed a moderate or good response was 47.8{\%} (11/23). The mean blood concentrations of tacrolimus in EULAR responders and EULAR non-responders were 5.5±3.6 (mean±S.D.) and 3.1±1.9 ng/ml, respectively (p = 0.069). Interestingly, although tacrolimus had lower mean blood concentrations (< 5ng/ml) compared with transplant fields (10-20 ng/ml), six (35.3{\%}) of 17 patients showed sufficient response to tacrolimus. In addition, in five patients, tacrolimus was co-administered with methotrexate (MTX). On the other hand, the mean blood concentrations of tacrolimus in patients who did or did not develop adverse events were 4.8±4.4 (n = 8) and 4.0±2.1 (n = 15) ng/ml, respectively (p = 0.624). We failed to clear the optimal blood concentration of tacrolimus in RA patients, but one of the most remarkable findings was the observation that patients in whom tacrolimus was combined with MTX reached a positive response at much lower tacrolimus concentrations compared to patients not co-treated with MTX.",
keywords = "Blood concentration, Rheumatoid arthritis, Tacrolimus, Therapeutic drug monitoring",
author = "Hitoshi Kawazoe and Hiroaki Dobashi and Tomohiro Kameda and Kentaro Susaki and Katuharu Kittaka and Michiaki Tokuda and Noriyasu Fukuoka and Toshihiko Ishida and Yoshiharu Takiguchi and Hitoshi Houchi",
year = "2009",
month = "6",
day = "1",
doi = "10.1248/jhs.55.435",
language = "English",
volume = "55",
pages = "435--440",
journal = "Journal of Health Science",
issn = "1344-9702",
publisher = "Pharmaceutical Society of Japan",
number = "3",

}

TY - JOUR

T1 - Prospective study to assess the optimal blood concentration of tacrolimus in Japanese patients with rheumatoid arthritis

AU - Kawazoe, Hitoshi

AU - Dobashi, Hiroaki

AU - Kameda, Tomohiro

AU - Susaki, Kentaro

AU - Kittaka, Katuharu

AU - Tokuda, Michiaki

AU - Fukuoka, Noriyasu

AU - Ishida, Toshihiko

AU - Takiguchi, Yoshiharu

AU - Houchi, Hitoshi

PY - 2009/6/1

Y1 - 2009/6/1

N2 - We performed a prospective study to assess the optimal blood concentration of tacrolimus in Japanese patients with rheumatoid arthritis (RA). The dose of tacrolimus (1-3mg/day) was administered orally once daily after the evening meal, and the blood concentration of tacrolimus 12 hr after administration was quantified. A total of 23 patients were enrolled. Clinical efficacy was assessed using the Disease Activity Score in 28 joints and European League Against Rheumatism (EULAR) response criteria at each outpatient visit during months 1-6. The ratio of patients who showed a moderate or good response was 47.8% (11/23). The mean blood concentrations of tacrolimus in EULAR responders and EULAR non-responders were 5.5±3.6 (mean±S.D.) and 3.1±1.9 ng/ml, respectively (p = 0.069). Interestingly, although tacrolimus had lower mean blood concentrations (< 5ng/ml) compared with transplant fields (10-20 ng/ml), six (35.3%) of 17 patients showed sufficient response to tacrolimus. In addition, in five patients, tacrolimus was co-administered with methotrexate (MTX). On the other hand, the mean blood concentrations of tacrolimus in patients who did or did not develop adverse events were 4.8±4.4 (n = 8) and 4.0±2.1 (n = 15) ng/ml, respectively (p = 0.624). We failed to clear the optimal blood concentration of tacrolimus in RA patients, but one of the most remarkable findings was the observation that patients in whom tacrolimus was combined with MTX reached a positive response at much lower tacrolimus concentrations compared to patients not co-treated with MTX.

AB - We performed a prospective study to assess the optimal blood concentration of tacrolimus in Japanese patients with rheumatoid arthritis (RA). The dose of tacrolimus (1-3mg/day) was administered orally once daily after the evening meal, and the blood concentration of tacrolimus 12 hr after administration was quantified. A total of 23 patients were enrolled. Clinical efficacy was assessed using the Disease Activity Score in 28 joints and European League Against Rheumatism (EULAR) response criteria at each outpatient visit during months 1-6. The ratio of patients who showed a moderate or good response was 47.8% (11/23). The mean blood concentrations of tacrolimus in EULAR responders and EULAR non-responders were 5.5±3.6 (mean±S.D.) and 3.1±1.9 ng/ml, respectively (p = 0.069). Interestingly, although tacrolimus had lower mean blood concentrations (< 5ng/ml) compared with transplant fields (10-20 ng/ml), six (35.3%) of 17 patients showed sufficient response to tacrolimus. In addition, in five patients, tacrolimus was co-administered with methotrexate (MTX). On the other hand, the mean blood concentrations of tacrolimus in patients who did or did not develop adverse events were 4.8±4.4 (n = 8) and 4.0±2.1 (n = 15) ng/ml, respectively (p = 0.624). We failed to clear the optimal blood concentration of tacrolimus in RA patients, but one of the most remarkable findings was the observation that patients in whom tacrolimus was combined with MTX reached a positive response at much lower tacrolimus concentrations compared to patients not co-treated with MTX.

KW - Blood concentration

KW - Rheumatoid arthritis

KW - Tacrolimus

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=66749100559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66749100559&partnerID=8YFLogxK

U2 - 10.1248/jhs.55.435

DO - 10.1248/jhs.55.435

M3 - Article

AN - SCOPUS:66749100559

VL - 55

SP - 435

EP - 440

JO - Journal of Health Science

JF - Journal of Health Science

SN - 1344-9702

IS - 3

ER -